The detection and/or quantification of circulating BRAF mutant alleles is correlated with presence of metastasis, drug response and clinical outcomes in melanoma patients, suggesting that circulating detection of a BRAF mutation can be a non-invasive molecular marker for disease monitoring and treatment selection [66,67]. This evidence concerns the gene BRAF and melanoma.